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Glaucoma is the leading cause of irreversible blindness worldwide. Loss of vision due to glaucoma is caused by the selective
death of retinal ganglion cells (RGCs). Treatments for glaucoma, limited to drugs or surgery to lower intraocular pressure (IOP),
are insufﬁcient. Therefore, a pressing medical need exists for more effective therapies to prevent vision loss in glaucoma
patients. In this in vivo study, we demonstrate that systemic administration of galantamine, an acetylcholinesterase inhibitor,
promotes protection of RGC soma and axons in a rat glaucoma model. Functional deﬁcits caused by high IOP, assessed
by recording visual evoked potentials from the superior colliculus, were improved by galantamine. These effects were not
related to a reduction in IOP because galantamine did not change the pressure in glaucomatous eyes and it promoted neuronal
survival after optic nerve axotomy, a pressure-independent model of RGC death. Importantly, we demonstrate that galantamine-
induced ganglion cell survival occurred by activation of types M1 and M4 muscarinic acetylcholine receptors, while nicotinic
receptors were not involved. These data provide the ﬁrst evidence of the clinical potential of galantamine as neuroprotectant for
glaucoma and other optic neuropathies, and identify muscarinic receptors as potential therapeutic targets for preventing vision
loss in these blinding diseases.
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Glaucoma is the leading cause of irreversible blindness
worldwide. It has been estimated that 450 million people
around the world are affected by this disease, with 47 million
presenting bilateral blindness.
1 Loss of vision due to glau-
coma is caused by the selective death of retinal ganglion cells
(RGCs), the output neurons that relay visual information from
the retina to the brain through their axons in the optic nerve.
Although the precise cause of RGC death in glaucoma is
unknown,highintraocular pressure(IOP) isa major risk factor
for developing this disease. Current treatments for glaucoma
are limited to lowering IOP by medication or surgery, but a
signiﬁcant number of patients continue to experience visual
loss despite responding well to pressure lowering therapies.
Moreover, 450% of patients have normal tension glaucoma
characterized by optic nerve degeneration in the absence of
high IOP.
2 Therefore, current therapies for glaucoma are
insufﬁcient and novel strategies to save RGCs and prevent
vision loss would be valuable.
Galantamine is a small molecule acetylcholinesterase
(AChE) inhibitor and allosteric ligand of nicotinic ACh
receptors (nAChR) currently used for the symptomatic
treatment of Alzheimer’s disease. Galantamine was initially
thought to ameliorate cognitive deﬁcits in Alzheimer’s disease
patients only due to its cholinergic boosting activity, but recent
studies have shown that it also has neuroprotective effects.
In vitro, galantamine protects cortical neurons from b-amyloid
toxicity and motor neurons from excess glutamate.
3,4 In vivo,
galantamine improves the survival of hippocampal neurons
following transient global ischemia and of dopamine neurons
damaged by 6-OHDA.
5,6 Pharmacological antagonists of
nAChR have been shown to partially reduce the neuro-
protective effect of galantamine against b-amyloid toxicity
in culture,
3,7 suggesting that nAChR may be involved
in galantamine-induced cell survival. However, the precise
mechanisms underlying neuroprotection mediated by galan-
tamine in vivo remain poorly deﬁned.
In this study, we examined the role of galantamine in the
visual system and investigated whether it stimulates RGC
survival in a rat glaucoma model. Our data demonstrate that
galantamine leads to structural protection of RGCs from
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www.nature.com/cddisocular hypertension (OHT) damage. We show that the
profound functional impairments caused by high IOP are
markedly attenuated in galantamine-treated eyes. Intrigu-
ingly, galantamine-induced RGC neuroprotection is mediated
through activation of muscarinic ACh receptors (mAChR),
and is independent of nAChR. Our study provides the
ﬁrst evidence of the therapeutic potential of galantamine
in glaucoma and reveals mAChR as a potential clinical target
for this neurodegenerative disease.
Results
Galantamine protects RGC soma and axons from
hypertension-induced death. We tested the neuro-
protective effect of galantamine in vivo in a rat OHT model
of glaucoma. Unilateral elevation of IOP was induced after a
single injection of hypertonic solution into an episcleral vein,
a procedure named OHT surgery. Gradual increase in eye
pressure and progressive death of RGCs was observed in
this model, with an excellent linear correlation between IOP
increase and degree of RGC loss and optic nerve damage.
8
Inner retinal atrophy, optic nerve degeneration and optic
nerve head remodeling in this model are similar to those
seen in human glaucoma, making this model one of the best
experimental in vivo paradigms to study glaucoma.
RGCs were visualized with the ﬂuorescent tracer DiI
(1,10-dioctadecyl-3,3,30,30-tetramethyl-indocarbocyanine per-
chlorate), which was applied to the superior colliculus at least
1 week before OHT surgery to ensure retrograde labeling
before any changes in optic nerve function caused by
experimental glaucoma (Figure 1a). Unlike other retrograde
markers that leak from the cell body after several weeks,
DiI has been shown to persist in RGCs in vivo for periods of
Figure 1 Galantamine protects RGC soma in glaucoma. (a) Outline of the experimental protocol used to test the effect of galantamine on RGC survival in experimental
glaucoma. RGCs were retrogradely labeled with the ﬂuorescent tracer DiI, and ocular hypertension (OHT) surgery was performed a week later. Galantamine treatment
(3.5mg/kg, i.p.) was initiated at B1 week after OHT surgery, and continued thereafter for the entire duration of the experiment. Retinas and optic nerves were examined
at 3 and 5 weeks following OHT surgery. (b) DiI-labeled RGCs in a ﬂat mount preparation from intact, uninjured Brown-Norway rat retina. At 5 weeks after OHT surgery,
galantamine treatment (c) led to higher neuronal densities and better preservation of cellular integrity compared with eyes treated with PBS (d). (e) Quantitative analysis of
RGC survival in experimentalglaucoma after treatment with galantamine (solid bars) or vehicle (PBS, hatched bars) (n¼9–11 rats per group). The density of RGCs in intact,
untreated Brown-Norway rat retinas (open bars) is shown as reference. Galantamine markedly increased the number of RGCs that survived at 3 and 5 weeks after OHT
surgery (ANOVA, ***Po0.001). Data are expressed as the mean±S.E.M. Scale bars (b–d): 100mm
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Cell Death and Diseaseup to 9 months without fading or leakage.
9 Consistent with
previous studies, the average total RGC population detected
by DiI in intact, non-injured Brown-Norway rat retinas was
1841±15RGCs/mm
2 (mean±S.E.M., n¼9) (Figures 1b
and e). Galantamine is a small molecule capable of crossing
the blood–brain and blood–retinal barriers; therefore, its
neuroprotective effect was evaluated after daily intraperito-
neal (i.p.) injection of 3.5mg per kg of body weight (mg/kg),
a dose selected based on previous studies showing efﬁcacy
in vivo.
5,6 Galantamine treatment was initiated once IOP
elevation was detected (B1 week after OHT surgery,
Figure 1a) and continued thereafter for the entire duration of
the experiment.
Analysis of DiI-positive RGCs in retinal whole mounts
showed that galantamine led to higher neuronal densities and
better preservation of cellular integrity in glaucomatous eyes
compared with control eyes treated with vehicle (phosphate-
buffered saline, PBS) (Figure 1b–d). Quantitative analysis
conﬁrmed that daily galantamine treatment led to a robust
increase in survival of injured RGCs at 3 weeks after OHT
surgery (90%: 1627±29RGCs/mm
2, mean±S.E.M., n¼11)
compared with vehicle (55%: 1025±22RGCs/mm
2, n¼9)
(one-way analysis of variance (ANOVA), Po0.001). Although
neuronal damage was more severe at 5 weeks after
OHT surgery, galantamine still protected 70% of RGC soma
(1270±74RGCs/mm
2, n¼10) compared with only 37%
with PBS (657±52RGCs/mm
2, n¼9) (ANOVA, Po0.001)
(Figure 1e). We carried out a comparative study on the
neuroprotective effect of galantamine with respect to
memantine, an N-methyl-D-aspartic acid channel blocker,
and donepezil, another AChE inhibitor, both currently used in
Alzheimer’s disease. Our results show that galantamine was
more effective than memantine or donepezil at preventing
RGC loss in experimental glaucoma (Figure 2).
Glaucoma is characterized by the degeneration of RGC
axons in the optic nerve posterior to the lamina cribrosa;
hence, we also investigated the effect of galantamine on
RGC axon protection. Analysis of optic nerve cross-sections
demonstratedalargernumberofRGCaxonﬁberswithnormal
morphology in galantamine-treated eyes compared with
PBS-treated control eyes (Figure 3a–c), the latter showing
extensive axon degeneration including disarray of fascicular
organization and degradation of myelin sheaths. Quantitative
analysis conﬁrmed that galantamine promoted substantial
protection of RGC axons from glaucomatous damage
(Figure 3d). Collectively, these results indicate that galanta-
mine effectively protects both RGC soma and axons in
experimental glaucoma.
Galantamine-mediated neuroprotection is not due to
decreased IOP. To investigate if daily treatment with galant-
amine led to IOP reduction, which could account for the
observed neuroprotective effect, we measured eye pressure
daily for 2 weeks after OHT surgery and then every other
day for the entire duration of the experiment. Our results
demonstrate that daily i.p. administration of galantamine did
not reduce IOP over a period of several weeks (Figure 4a).
The mean sustained pressure elevation among galantamine-
treated and PBS-treated groups was similar: B34mmHg
at 3 weeks after OHT surgery and B40mmHg at 5 weeks
after OHT surgery (Table 1), well within the range of IOP
increases observed in this model.
8 Given that the rate
of RGC death is proportional to IOP, the similar elevation in
IOP among groups allowed for reliable comparison of the
neuroprotective effect of galantamine versus vehicle.
Tofurthertestwhethergalantamine-mediatedneuroprotec-
tion was independent of IOP-induced damage, we examined
the effect of galantamine after axotomy of the optic nerve
(Figure 4b–e), an acute insult that leads to rapid apoptotic
death of RGCs. RGCs were retrogradely labeled with Fluoro-
gold and subjected to optic nerve transection with conco-
mitant intraocular injection of galantamine. The average
total RGC population detected with Fluorogold in intact, non-
injured Sprague–Dawley rat retinas was 2223±24RGCs/mm
2
(mean±S.E.M., n¼5), a slightly higher density than in Brown-
Norway rats, consistent with previous studies.
10 After axotomy,
allRGCssurvivefor5daysandthendieabruptly:thepopulation
of RGCs is reduced to B50% by 1 week and to B10% at
2 weeks after axotomy. In galantamine-treated eyes, 75% of
RGCs survived at 1 week after axotomy compared with 50%
that survived in the PBS-treated group (1611±47RGCs/mm
2,
n¼6 and 920±32RGCs/mm
2, n¼5, respectively, ANOVA,
Po0.001). The effect of galantamine was still marked at
2 weeks after axotomy: 30% of all RGCs remained alive
compared with only 10% survival in PBS-treated eyes
(616±30RGCs/mm
2, n¼5 and 216±15RGCs/mm
2, n¼5,
respectively, ANOVA, Po0.01) (Figure 4e). Collectively,
these results demonstrate that galantamine can delay RGC
loss after chronic (glaucoma) or acute (axotomy) optic nerve
injury.
RGC functional deﬁcits in glaucoma are improved by
galantamine. Our results show structural protection of
RGCs, both at the level of the cell bodies and axons, but
are these neurons functional? To investigate whether galant-
amine preserved RGC function in glaucoma, we measured
visual evoked potentials (VEPs) after ﬂash stimulation. The
main target of RGCs in the rat brain is the superior colliculus,
thus VEPs recorded from this region provide a faithful
representation of surviving RGC function and were used as
the primary outcome to assess functional neuroprotection.
Figure 2 Comparative analysis of RGC survival in experimental glaucoma
mediated by galantamine (solid bars), memantine (crossed hatched bars), donepezil
(vertical lines) or vehicle (PBS, hatched bars) at 3 and 5 weeks after OHT (n¼7–11
rats per group) (ANOVA, ***Po0.001). Data are expressed as the mean±S.E.M.
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Cell Death and DiseaseThe ﬂash electroretinogram (ERG) provides information
about the outer retina and was not used to assess RGC
function. ERGs were routinely performed before VEPs to
ensure that the outer retina was functioning properly and
that RGCs received adequate input after visual stimulation.
All the animals in this study had normal ERGs.
First, we investigated whether galantamine daily treatment
had any effect on the VEP response to ﬂash stimulation
in normal, non-glaucomatous eyes. Our data demonstrate
that VEPs recorded from galantamine-treated normal
brains were indistinguishable from those treated with PBS
or without treatment (Figure 5a), indicating that galant-
amine by itself does not alter the response of normal RGCs
or target neurons in the superior colliculus. At 3 weeks
after OHT surgery, examination of VEP responses to ﬂash
stimulation showed substantial reduction in evoked currents
recorded from PBS-treated eyes compared with intact,
non-glaucomatous controls (Figure 5b). In contrast, galanta-
mine administration led to marked preservation of the VEP.
Quantiﬁcation of peak-to-peak VEP amplitudes demonstrated
that galantamine preserved 66% of the intact VEP response
compared with only 30% in PBS-treated controls (ANOVA,
Po0.001).
At 5 weeks after OHT surgery, both PBS-treated and
galantamine-treated glaucomatous eyes showed complete
obliteration of the VEP (Figure 5c). This lack of response
could not be solely attributed to RGC degeneration
because galantamine protected almost 70% of RGC soma
and axons at 5 weeks after OHT (Figures 1 and 3). We then
hypothesized that sustained high IOP impairs the visual
functionofthesurvivingRGCs. Totest thisidea,weevaluated
the effect of galantamine on the VEP response using a
protocol in which IOP in the glaucomatous eye was controlled
by topical (corneal) application of timolol, a commonly used
b-adrenergic receptor blocker. Treatment with timolol
began at 3 weeks after OHT and continued for the entire
duration of the experiment. Timolol limited the IOP increase
in galantamine-treated glaucomatous eyes to a mean IOP
of 35.6mmHg compared with 42.7mmHg in eyes with-
out timolol (Table 1). Interestingly, this difference in IOP
(7mmHg) was sufﬁcient to restore 47% of the VEP response
in galantamine-treated eyes, but not in PBS-treated eyes
(Figure 5c), indicating that IOP reduction only rescued RGC
function when combined with galantamine. The recovery of
VEP was not due to a neuroprotective effect of timolol because
animals treated with PBS and timolol did not show any
functional improvement. Furthermore, VEP recovery was not
due to increased survival because RGC densities in the
presence of timolol and galantamine (1387±50RGCs/mm
2,
mean±S.E.M., n¼8)werenotstatisticallydifferentfromthose
in eyes treated with galantamine alone (1270±85RGCs/mm
2,
n¼10, P40.05). The absence of VEP responses in eyes
treated with PBS also conﬁrmed that topical application of
timolol, by itself, was not neuroprotective. Taken together,
these results indicate that high IOP leads to dramatic deﬁcits
in retinal function that can be markedly attenuated by
Figure 3 Galantamine protects RGC axons in glaucoma. Cross-sections of optic nerve segments from intact (a) and glaucomatous eyes treated with galantamine (b)
or PBS (c) at 5 weeks after ocular hypertension (OHT) surgery. Galantamine-treated eyes displayed a larger number of axonal ﬁbers with normal morphology compared
with PBS-treated control eyes, which showed extensive axon degeneration. (d) Quantitative analysis of RGC axons in the optic nerve following daily i.p. injection of
galantamine (solid bar) or PBS (hatched bar) (n¼8–9 rats per group) (ANOVA, ***Po0.001). The number of axons in the intact, uninjured Brown-Norway rat optic nerve
is shown as reference (open bar). Data are expressed as the mean±S.E.M. Scale bars (a–c): 20mm
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Cell Death and DiseaseFigure 4 Galantamine-mediated neuroprotection is not due to decreased intraocular pressure. (a) Daily i.p. administration of galantamine did not reduce intraocular
pressure (IOP) over a period of several weeks. (b) Fluorogold-labeled RGCs in a ﬂat mount preparation from intact, uninjured Sprague–Dawley rat retina. (c) Galantamine
treatmentled to marked survival of axotomizedRGCs with respect to PBS-treated eyes(d). (e) Quantitative analysisof RGCsurvival after intraocular injectionof galantamine
(solid bars) or PBS (hatched bars) (n¼5–6 rats per group) (ANOVA, ***Po0.001). The density of RGCs in intact, uninjured Sprague–Dawley rat retinas is shown as
reference (open bar). Data are expressed as the mean±S.E.M. Scale bars (a–c): 100mm
Table 1 Intraocular pressure (IOP) elevation in glaucomatous eyes
Mean IOP (mmHg) Peak IOP (mmHg)
Time after OHT surgery Group N Glaucoma Control Difference Glaucoma Control
3 weeks Galantamine 27 34.71±1.8 22.41±0.2 11.09±2.4 39.45±1.4 26.81±1.3
Vehicle 23 33.11±1.6 22.59±0.3 11.73±0.3 38.23±1.2 25.67±1.6
No treatment 7 34.11±0.6 23.09±0.2 11.02±0.4 38.41±0.9 26.25±1.2
P-value (ANOVA) 0.6 0.12 — 0.41 0.85
5 weeks Galantamine 23 42.71±0.2 23.63±1.5 17.08±0.8 49.11±4.2 25.11±0.5
Vehicle 22 39.11±1.0 23.4±2.0 16.73±1.0 48.17±1.0 26.55±0.7
Ga l+ Timolol 6 35.64±0.8 22.11±2.2 13.53±1.4 41.80±0.8 26.05±2
Vehicle+Timolol 6 34.54±1.6 22.23±1.3 12.31±0.5 42.36±0.5 26.28±4.2
No treatment 10 41.35±0.8 22.80±1.7 17.55±1.7 49.65±0.9 25.08±0.9
P-value (ANOVA) 0.45 0.12 — 0.32 0.71
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Cell Death and DiseaseFigure 5 RGC functional deﬁcits in glaucoma are improved by galantamine. (a) Visual evoked potentials (VEP) recorded from galantamine-treated normal brains were
indistinguishable from those treated with PBS or without treatment. (b) At 3 weeks after OHT surgery, galantamine administration led to marked preservation of the VEP
responses (ANOVA, *Po0.001). (c) At 5 weeks after OHT surgery, both PBS-treated and galantamine-treated glaucomatous eyes showed complete obliteration of the VEP
response. Daily application of Timolol drops on the cornea was sufﬁcient to restore the VEP response in galantamine-treated eyes but not in PBS-treated eyes (ANOVA,
*Po0.001)
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Cell Death and Diseasegalantamine, and highlight the importance of combining
galantamine with IOP-lowering drugs to achieve long-term
functional RGC protection.
ACh muscarinic, but not nicotinic, receptors mediate the
neuroprotective effect of galantamine in experimental
glaucoma. In the nervous system, there are two major types
of ACh receptors: (i) nicotinic receptors (nAChR) including
the a7 and the a4b2 nAChR, which are the most abundant
subtypes in the brain, and metabotropic mAChRs, which
are selectively activated by muscarine-like ligands and
include ﬁve distinct isoforms (M1–M5) corresponding to the
products of ﬁve separate genes.
11 To gain mechanistic
insight into how galantamine promotes RGC neuroprotection
in vivo, we asked whether blockade of nAChR or mAChR
would compromise galantamine-induced RGC survival.
For this purpose, we ﬁrst assessed the survival of axoto-
mized RGCs after intraocular injection of galantamine in
combination with selective pharmacological blockers of
nAChR or mAChR. Co-injection of galantamine with
scopolamine, an inhibitor of all mAChR types, abrogated
the prosurvival effect of galantamine. In contrast, co-
administration of galantamine with either methyllycaconitine
(MLA), a speciﬁc antagonist of a7nAChR, dihydro-b-erythroi-
dine (DHb-E), a speciﬁc antagonist of a4b2nAChR, or
mecamylamine (MMA), a blocker of all neuronal nAChR did
not reduce galantamine-induced RGC survival (Figure 6a).
A range of concentrations of these nAChR inhibitors was
tested (10mM to 10mM) with similar outcome, indicating
that their lack of effect was not the result of suboptimal doses
of these drugs. Consistent with these ﬁndings, daily i.p.
co-injection of galantamine and scopolamine, which readily
cross the blood–brain/retinal barrier, completely inhibited
RGC neuroprotection in glaucomatous eyes at 5 weeks after
OHT (Figure 6b). Administration of MLA, DHb-E, MMA or
scopolamine, by themselves, did not cause RGC death
or adverse effects in non-injured retinas, nor did they
promote survival in injured rat retinas at the doses used
here (Figure 6c and d).
Toestablishwhich mAChRswere involved inRGC survival,
the following selective antagonists of mAChR subtypes
were co-administered with galantamine: pirenzepine (M1),
DX116 (M2), 4-DAMP (M3) or tropicamide (M4). These
mAChR antagonists do not cross the blood–brain/retinal
barrier or exhibit extremely low-barrier permeability,
12,13 thus
their effect was tested on galantamine-induced protection of
axotomized RGCs after intraocular injection. Figure 6e shows
that while blockade of M2 by DX116 or M3 by 4-DAMP did not
have any effect on RGC survival mediated by galantamine,
blockade of M1 with pirenzepine completely abrogated RGC
neuroprotection. TheM4 antagonist tropicamide also reduced
RGC survival, albeit to a lesser extent than pirenzepine.
Collectively, these data strongly suggest that M1 and
M4mAChR are mediators of galantamine-induced RGC
neuroprotection.
Discussion
This study supports four major ﬁndings. First, galantamine
treatment leads to survival of RGC soma and axons in
experimental glaucoma. Second, galantamine-mediated
RGC structural protection is independent of IOP-induced
damage, as evidenced by the neuroprotective action of
this drug after optic nerve axotomy. Third, functional deﬁcits
caused by high IOP are markedly improved by galant-
amine. Fourth, galantamine-mediated neuroprotection
occurs primarily through activation of retinal mAChR M1,
and is independent of nAChR.
Several recent clinical studies have suggested a correlation
between glaucoma and Alzheimer’s disease,
14 but the most
compelling evidence supporting such link stems from labora-
tory work. For example, neuronal loss in both glaucoma and
Alzheimer’s disease occurs by apoptosis,
15 caspases are
activated both in Alzheimer’s disease and in injured RGCs,
16
and intraocular injection of b-amyloid has been shown to
induce RGC degeneration.
17 More recently, b-amyloid de-
position was associated with RGC death in experimental
glaucoma and blockade of the b-amyloid pathway reduced
glaucomatous damage.
18 Although the etiology of glaucoma
and Alzheimer’s disease may differ, their common features
raise the provocative idea that drugs currently used to treat
Alzheimer’s disease may also have utility in glaucoma. Here,
we show that one such drug, galantamine, is a powerful
neuroprotectant for injured RGCs. Daily galantamine treat-
ment promoted the survival of RGC soma and axons in
glaucoma. Importantly, administration of galantamine by
intravitreal injection also led to robust RGC protection
after axotomy of the optic nerve. These data highlight
several important properties of galantamine: it is effective
when administered systemically or by intraocular injection,
it promotes structural protection of RGCs in an IOP-
independent manner and it delays RGC loss in different
models, both acute and chronic, of optic nerve damage.
The neuroprotective effect of galantamine was superior to
that conferred by memantine or donepezil. Galantamine has
been shown to be a weaker AChE inhibitor than donepezil,
19
therefore other factors likely account for this difference in
neuroprotective efﬁcacy. First, donepezil is a non-competitive
inhibitor of AChE, which may result in the development
of tolerance to donepezil and consequent downregulation of
ACh receptors.
20 In contrast, galantamine is a competitive
AChE inhibitor and the galantamine–AChE complex follows
the typical kinetics of reversible inhibitors, dissociating readily
in the presence of excess ACh, with a reduced potential for
tolerance.
21 Second, galantamine acts more broadly on other
neurotransmitter systemsandhasbeen showntoregulate the
release of glutamate, serotonin and g-aminobutyric acid,
22,23
thus potentially modulating neural activity and delaying
neurodegeneration. Third, mAChR are amenable to modula-
tion at allosteric sites;
24 hence, it is possible that galantamine
may activate mAChR directly, although this possibility
presently remains unknown.
Patients with glaucoma experience diminished visual
function and poor quality of life; therefore, an ideal neuro-
protective drug should preserve the structural viability of
RGCs while retaining their ability to respond to visual stimu-
lation.Inthisstudy,weaimedatprovidingastructure–function
link based on the neuroprotective effect of galantamine. Our
results show that there are major visual deﬁcits in glaucoma-
tous eyes treated with PBS, whereas galantamine treatment
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Cell Death and Diseaseled to substantial preservation of the VEP amplitude at
3 weeks after OHT. Of interest, following longer periods of
OHT (5 weeks) galantamine-protected RGCs (70%) did not
respond to light stimulation unless IOP was also reduced.
An IOP decrease of just a few mmHg was sufﬁcient to restore
almost 50% of the VEP response in galantamine-treated
Figure 6 The neuroprotective effect of galantaminein glaucomais mediatedby activation of AChmuscarinic receptors.(a) Co-injection of galantamine with scopolamine,
an inhibitor of all mAChR types, abrogatedthe prosurvival effect of galantamine. In contrast, the a7nAChRantagonist methyllycaconitine (MLA), the a4b2nAChR antagonist
dihydro-b-erythroidine (DHb-E) or the antagonist of all nAChR mecamylamine (MMA) did not reduce galantamine-induced survival of axotomized RGCs (ANOVA,
*Po0.001). (b) Co-administration of galantamine and scopolamine (SCO) completely inhibited galantamine-induced RGC neuroprotection in glaucomatous eyes at 5 weeks
after OHT (ANOVA, *Po0.001). Administration of MLA, DHb-E, MMA or SCO, by themselves, did not cause RGC death or adverse effects in non-injured retinas (c), nor did
they promote survival in injured rat retinas (d)( n¼3–6/group). (e) Injection of galantamine in combination with the M1 mAChR blocker pirenzepine (PRZ), the M2 mAChR
antagonist DX116, the M3 mAChR blocker 4-DAMP or the M4 mAChR antagonist tropicamide (TRO), showed that galantamine-induced neuroprotection is mediated through
activation of M1 and M4 mAChR (ANOVA, *Po0.001)
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Cell Death and Diseaseeyes, but not in PBS-treated controls. The observation that
the majority of RGCs exposed to galantamine remained alive
at 5 weeks of OHT, but did not respond to light stimulation,
suggests that sustained high IOP has additional deleterious
effects on RGC function. We conclude that, in the long-term,
structural protection alone is not sufﬁcient to restore visual
function unless IOP is also controlled.
Galantamine increases the availability of ACh through its
inhibitory action on AChE, the enzyme responsible for ACh
breakdown, and it is also an allosteric modulator of nAChR
enhancing their sensitivity to ACh.
25 ACh in the retina is
released by starburst cholinergic amacrine cells onto RGC
dendrites and has a crucial role in visual information
processing.
26 Therefore, we postulated that galantamine-
induced neuroprotection might result from stimulation of ACh
receptors. As galantamine is an allosteric modulator of
nAChR, its neuroprotective effect has been compared with
that of nicotine. In fact, nicotine has been shown to promote
neuronal survival in different models of neurodegeneration
through nAChR and downstream activation of survival path-
ways.
27 Previous in vitro studies showed that galantamine
promoted the survival of cortical neurons or neuroblastoma
cells by a7nAChR and stimulation of phosphatidylinositol-3-
kinase (PI3K).
3,7 As RGCs express several nAChR subtypes
including a7nAChR,
28 we initially postulated that nAChR
activation would contribute to galantamine-mediated neuro-
protection. Surprisingly, our data show that the blockade
of nAChR had no effect, whereas inhibition of mAChR
completelycurtailed the neuroprotective effect of galantamine
in vivo. The total blockade of galantamine-induced neuro-
protection in the presence of mAChR inhibitors indicates that
these receptors are the primary locus of the speciﬁc action
of galantamine in the retina.
Immunocytochemical studies on the localization of mAChR
subtypes in primate, rat and chick retinas showed that M2 and
M4 are expressed by amacrine cells, and M3 is expressed
primarily by bipolar cells.
29–31 In addition, Mu ¨ller cells, the
mostabundantglialcelltypeinthemammalianretina,express
M1 and M4 mAChR types.
32 Muscarine was shown to
increase intracellular Ca
þ2 in rabbit RGCs;
33 however, this
effect was thought to be indirect because expression of
mAChR has not been detected in isolated rat or cat RGCs,
and muscarine did not elicit membrane currents measured
in whole-cell patch clamp preparations.
34 Our results indicate
that galantamine-mediated RGC neuroprotection in vivo
occurs primarily by activation of M1, a mAChR subtype
expressed by Mu ¨ller cells. The M4 mAChR subtype, expres-
sed by both Mu ¨ller glia and amacrine cells, also contributes to
this effect but to a lesser extent than M1mAChR. Collectively,
these data support a model in which non-cell-autonomous
signaling events downstream of mAChR have a major role
in galantamine-induced RGC neuroprotection. Activation of
M1/M4 mAChR on neighboring Mu ¨ller glia and amacrine cells
may lead to stimulation of signaling pathways and production
of prosurvival factors that protect injured RGCs. Other retinal
cell types that express these mAChR subtypes, including
endothelial cells,
35 may also participate in galantamine-
mediated RGC survival.
M1 and M4 mAChR are G-protein-coupled receptors linked
to different signal-transduction pathways. M1mAChR are
preferentially coupled to pertussis toxin (PTX)-insensitive
Gq/G11 proteins that stimulate phospholipase C (PLC) and
phosphatidylinositol hydrolysis with subsequent Ca
þ2 mobi-
lization from intracellular stores. M4 mAChR, on the other
hand, are preferentially coupled to PTX-sensitive Gi/o proteins
that inhibit adenylate cyclase and regulate intracellular cAMP
levels. It has become increasingly clear that mAChR down-
stream signaling pathways converge or intersect with media-
tors of cell survival. For example, M4 mAChR interacts with
the nerve growth factor receptor, through Gbg complexes, to
enhance PI3K/Akt activation and neuronal survival.
36 Of
interest, M1 mAChR through Gaq and PLC leads to activation
of Nrf2, a transcription factor involved in redox homeostasis,
which may increase the cellular antioxidant defenses and
confer neuroprotection against oxidative stress.
37 Moreover,
M1 mAChR activation also regulates the activity of the
hypoxia-inducible factor-1, a transcription factor involved in
the cellular response to hypoxia.
38 Oxidative stress and
ischemia/hypoxia have been proposed to be major contribu-
tors to glaucomatous neurodegeneration. An important
priority in future studies will be to determine the M1- and
M4-coupled signaling pathways underlying galantamine-
induced RGC neuroprotection. The precise delineation of
these molecular events should be useful for the design
of novel therapeutic interventions applicable to glaucoma.
In summary, our study reveals the potent role of galanta-
mine in the protection of RGC structure and function in
glaucoma, which could be used in conjunction with standard
pressure controlling drugs. Our data also identify retinal
mAChR as a novel therapeutic target for prevention of
neuronal death and vision loss in optic neuropathies.
Materials and Methods
Experimental animals. All procedures were carried out in accordance with
the guidelines of the Society for Neuroscience, the Association for Research in
VisionandOphthalmology, andtheCanadianCouncilon Animal Carefor theuse of
experimental animals. OHT surgery was performed in aging, male Brown-Norway
rats (Charles River, Stone Ridge, NY, USA), retired breeders between 10 and
12 months of age (300–400g). Brown-Norway rats were used because they have
a larger eye suitable for the OHT surgical procedure, and this glaucoma model
has been well characterized in these animals.
8 The optic nerve axotomy model,
which is independent of OHT damage, was used as an acute paradigm of RGC
death and was carried out in adult Sprague–Dawley rats (Charles River Canada,
Saint-Constant, QC, Canada, 180–200g). The number of animals used in each
experiment is indicated above the bar in the corresponding graph.
Retrograde labeling of RGCs. For quantiﬁcation of neuronal survival,
RGCs were retrogradely labeled with DiI (Molecular Probes, Junction City, OR,
USA) for the glaucoma model, or with Fluorogold (2%, Fluorochrome, Englewood,
CO, USA) for the axotomy model. DiI crystals (3%) or Fluorogold (2%) were
dissolved in 0.9% NaCl containing 10% dimethyl sulfoxide and 0.5% Triton X-100.
The superior colliculus was exposed and a small piece of gelfoam (Pharmacia and
Upjohn, Mississauga, ON, Canada) soaked in tracer was applied to the surface.
Seven days after tracer application, the time required for labeling the entire RGC
population, animals were subjected to OHT surgery or axotomy.
Ocular hypertension surgery and optic nerve axotomy. Surgical
procedures were performed under general anesthesia by i.p. injection of 1ml/kg
standard rat cocktail consisting of ketamine (100mg/ml, Bimeda-MTC Animal
Health, Cambridge, ON, Canada),xylazine(20mg/ml,Bimeda-MTCAnimalHealth)
and acepromazine (10mg/ml, Ayerst Veterinary Laboratories, Guelph, ON,
Canada). Unilateral elevation of IOP was induced as previously described
8 by a
single injection of a hypertonic saline solution into an episcleral vein. A plastic ring
was applied to the ocular equator to conﬁne the injection to the limbal plexus and a
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Cell Death and Diseasemicroneedlewas then usedto inject 50ml of sterile 1.85M NaCl solutionthrough an
episcleral vein. The plastic ring temporarily blocks off other episcleral veins forcing
the saline solution into the Schlemm’s canal to create isolated scarring. After
injection, the plastic ring was removed and the eyes were examined to assess the
extent to which the saline solution traversed the limbal vasculature. Polysporin
ophthalmic ointment (Pﬁzer Canada, Kirkland, QC, Canada) was applied to the
operatedeyeandtheanimalwasallowedtorecoverfromthesurgery.Animalswere
kept in a room with constant low ﬂuorescent light (40–100 lux) to stabilize circadian
IOP variations. For optic nerve axotomies, animals were deeply anesthetized
(2% isoﬂurane, 0.8l/min), the left optic nerve was exposed and carefully transected
at 0.5–1mm from the optic nerve head avoiding injury to the ophthalmic artery.
Fundus examination was routinely performed immediately after axotomy and
3–5 days later to check the integrity of the retinal circulation after surgery. Animals
showing signs of compromised blood supply were excluded from the study.
Measurement of IOP. IOP from glaucomatous and normal eyes was
measured in awake animals because general anesthetics reduce IOP.
39
A calibrated tonometer (TonoPen XL, Medtronic Solan, Jacksonville, FL, USA)
was used to measure IOP after application of one drop of proparacaine
hydrochloride (0.5%, Alcon Laboratories, Fort Worth, TX, USA) per eye. The
tonometer was held exactly perpendicular to the corneal surface and B10
consecutive readings per eye were taken and averaged to obtain an accurate
IOP measurement. IOP was measured daily for 2 weeks after OHT surgery,
then every other day for the entire duration of the experiment. The mean and
peak (maximum) IOP for each eye were calculated and these values were used
to estimate the mean and peak IOP for experimental and control groups.
Drug delivery. Drug delivery in the glaucoma model was carried out by daily
i.p. injection to avoid multiple intraocular injections, which lead to IOP reduction
in glaucomatous eyes. For this purpose, the following compounds that cross
the blood–brain/retinal barrier were administered alone or in combination:
galantamine hydrobromide (3.5mg/kg, Tocris Bioscience, Ellisville, MO, USA),
memantine hydrochloride (4mg/kg, Sigma-Aldrich, St. Louis, MO, USA), donepezil
hydrochloride (4mg/kg, Jubilant Organosys, Stamford, CT, USA) or scopolamine
hydrobromide (1mg/kg, Tocris Bioscience). Control animals received daily
i.p. injections of sterile vehicle (PBS). In some experiments, animals were treated
with the b-adrenergic receptor blocker timolol maleate (0.5%, Sabex, Boucherville,
QC, Canada) applied daily on the cornea of the glaucomatous eye to control
IOP increase.
In the axotomy model, drug delivery was carried out by intravitreal injection of
the following compounds in a total volume of 5ml: galantamine hydrobromide
(100mM), MLA citrate (10mM, Sigma-Aldrich), dihydro-b-erythroidine hydro-
bromide (DHb-E, 100mM, Sigma-Aldrich), mecamylamine hydrochloride (MMA,
10mM, Sigma-Aldrich), scopolamine hydrobromide (10mM, Tocris Bioscience),
pirenzepine dihydrochloride (1mM, Tocris Bioscience), 11-[[2-[(Diethylamino)-
methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one
(DX116, 1mM, Tocris Bioscience), Diphenylacetoxy-N-methylpiperidine methiodide
(4-DAMP, 1mM, Tocris Bioscience) or tropicamide (1mM, Tocris Bioscience).
Control eyes received an intravitreal injection of sterile vehicle (PBS). Drugs were
injected into the vitreous chamber using a 10-ml Hamilton syringe adapted with a
32-gauge glass microneedle, the tip of which was inserted into the superior
hemisphere of the eye, at a B451 angle, through the sclera into the vitreous body.
This route of administration avoided retinal detachment or injury to eye structures,
including the iris and lens that release factors that may induce RGC survival.
Surgical glue (Indermill, Tyco Health Care, Mansﬁeld, MA, USA) was used to seal
the injection site.
Quantiﬁcation of RGC soma and axons. Quantiﬁcation of RGC bodies
and axons was performed in duplicate by an observer masked to the treatment
assignments. For RGC density counts, rats were deeply anesthetized and perfused
transcardially with 4% paraformaldehyde (PFA) in 0.1M phosphate buffer following
which both eyes were immediately enucleated. Retinas were dissected and ﬂat-
mounted on a glass slide with the ganglion cell layer side up. RGCs were counted
within three square areas at distances of 1, 2 and 3mm from the optic disc in each
of the four retinal quadrants (superior, inferior, nasal and temporal) for a total of
12 retinal areas. Macrophages and microglia that may have incorporated
ﬂuorescent tracer after phagocytosis of dying RGCs were excluded from our
quantitative analysis based on cell-speciﬁc markers and morphology.
40 For axon
counts, animals received a transcardial injection of heparin (1000m/kg) and sodium
nitropruside (10mg/kg) followed by perfusion with 2% PFA and 2.5%
glutaraldehyde in 0.1M phosphate buffer. Optic nerves were dissected, ﬁxed in
2% osmium tetroxide, and embedded in epon resin. Semi-thin sections (0.7-mm-
thick) were cut on a microtome (Reichert, Vienna, Austria) and stained with
1% toluidine blue. RGC axons were counted at 1mm from the optic nerve head
in ﬁve non-overlapping areas of each optic nerve section, encompassing a total
area of 5500mm
2 per nerve. The ﬁve optic nerve areas analyzed included: one in
the center of the nerve, two peripheral dorsal and two peripheral ventral regions.
The total area per optic nerve cross-section was measured using Northern Eclipse
imageanalysissoftware(EmpixImaging,Toronto,ON,Canada),andthisvaluewas
used to estimate the total number of axons per optic nerve.
Visual evoked potential and electroretinogram recordings. For
VEP recordings, animals were anesthetized with isoﬂurane (3% for induction and
1.5% for maintenance) and placed in a stereotaxic head holder. The ERG was
continuously monitored and the core body temperature was maintained at 371C
using a feedback controlled heating pad. Atropine sulfate eye drops (1%, Allergan
Canada, Markham, ON, Canada) were used to dilate the pupils, and the corneas
were protected by application of artiﬁcial tears (Allergan Canada). A bilateral
craniotomy was performed anterior to the lambda, at bregmacoordinates  6.8 and
1.5mm lateral to the sagittal suture, to expose the cerebral cortex overlying the
superior colliculus of each hemisphere. The dura was then incised and a tungsten
multiunit recording microelectrode (impedance 0.8O Microprobe, Gaithersburg,
MD, USA) was lowered under microscopic view until the tip touched the surface of
the cortex. The skull opening was then ﬁlled with agar to protect the tissue from
desiccation and, using a micromanipulator (Motorized Microdrive, FHC,
Bowdoinham, ME, USA), the microelectrode was advanced vertically to 300mm
from the superﬁcial layer of the superior colliculus into the stratum griseum
superﬁciale. Visual stimulation was provided by a diffuse ﬂash (f¼1Hz, Grass
photostimulator, Astro-Med, Brossard, QC, Canada) placed 30cm away from the
contralateral eye. Triggered evoked potentials were averaged over 40 successive
presentations. VEP signals were ampliﬁed and bandpass ﬁltered between 10 and
1000Hz and acquired by an analogue/digital interface (CED 1401 plus) to a PC
running acquisition software (Signal 2, CED, Cambridge, UK). At the end of the
experiment, the ﬁnal electrode location was marked by passing a direct current of
10mA for 5s through the recording electrode. The animals were then perfused with
4% PFA, the brains were removed and processed for serial sectioning. Sections
(50mm) were stained with cresyl violet and the electrode location mark was
visualized as an iron precipitate following incubation in a 2% K4Fe(CN)6 solution.
The depth of recording was conﬁrmed by the position of the mark and the depth
reading of the micromanipulator.
ForERGrecordings,animalsweredarkadaptedfora12-hperiod.Underdimred
light illumination, the animals were anesthetized with a mixture of ketamine
hydrochloride (80mg/kg) and xylazine (6mg/kg), and the pupils were dilated with
cyclopentolate hydrochloride 1%. ERGs were recorded with a Dawson, Trick and
Litzkow ﬁber electrode (27/7X-Static, silver-coated conductive nylon yarn, Sauquoit
Industries, Scranton, PA, USA) that was positioned and maintained on the cornea
using a drop of 1% methylcellulose. The ERG (bandwidth: 1-1000Hz;  10000;
Grass, P511 ampliﬁer) and oscillatory potentials (bandwidth: 100–1000Hz;
 50000) were recorded simultaneously with the Acknowledge data acquisition
system (Biopac MP 100 WS, BIOPAC System, Goleta, CA, USA).
Statistical analysis. Data analysis and statistics were performed using the
GraphPad Instat software (GraphPad Software, San Diego, CA, USA) by a ANOVA
test followed by Bonferroni’s multiple comparison post-test.
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